Open AccessLong-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Author(s) -
Anthony Mills,
Gary Richmond,
Cheryl Newman,
Olayemi Osiyemi,
Jerry Cade,
Cynthia Brinson,
Jerome De Vente,
David Margolis,
Ken Sutton,
Viviana Wilches,
Sarah Hatch,
Jeremy Roberts,
Cynthia McCoig,
Cindy Garris,
Kati Vandermeulen,
William Spreen
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000003085
Subject(s) - rilpivirine , dosing , medicine , dolutegravir , adverse effect , human immunodeficiency virus (hiv) , viral load , clinical endpoint , clinical trial , virology , antiretroviral therapy
Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral activity and safety of CAB+RPV long-acting administered every 2 months (Q2M) in adults living with HIV-1 who previously received daily oral CAB+RPV in LATTE (NCT01641809).